Immunotherapy has revolutionized the field of oncology by utilizing the body's immune system to fight cancer. This article aims to provide physicians with an in-depth understanding of this groundbreaking treatment modality.
Immunotherapy works by enhancing the immune response against cancer cells. It includes a range of treatment options such as immune checkpoint inhibitors, cancer vaccines, and adoptive cell transfer. These therapies can be used alone or in combination with other treatments to increase their effectiveness.
Immune checkpoint inhibitors are drugs that block immune checkpoints. These checkpoints are proteins that prevent immune cells from attacking normal cells in the body. By blocking these checkpoints, the drugs allow immune cells to respond more strongly to cancer. Key checkpoint inhibitors include PD-1/PD-L1 inhibitors and CTLA-4 inhibitors.
Cancer vaccines, unlike traditional vaccines, are usually given after a cancer diagnosis to stimulate the immune system to attack cancer cells. These vaccines can be specific to a type of cancer or customized to an individual patient's cancer.
Adoptive cell transfer involves modifying a patient's immune cells to enhance their ability to fight cancer. CAR-T cell therapy, a form of adoptive cell transfer, has shown promising results in treating certain types of leukemia and lymphoma.
While immunotherapy has proven effective, it's not suitable for every patient. Physicians must consider factors like the type and stage of cancer, patient health, and previous treatments. Side effects can range from mild to severe and may include fatigue, pain, and immune-related adverse events.
Immunotherapy is a powerful tool in the fight against cancer. As our understanding of the immune system and cancer biology continues to grow, so too will the potential of immunotherapy. It's crucial for physicians to stay updated on this rapidly evolving field to provide the best possible care for their patients.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation